

**ZEPZELCA
(lurbinectedin)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Metastatic small cell lung cancer (SCLC)

AND ALL of the following:

- a. Disease progression on or after platinum-based chemotherapy
- b. Baseline neutrophil count is $\geq 1,500$ cells/mm³
- c. Baseline platelet count is $\geq 100,000$ /mm³
- d. Prescriber agrees to monitor for myelosuppression and hepatotoxicity
- e. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zepzelca and for 6 months after the final dose
- f. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zepzelca and for 4 months after the final dose

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Metastatic small cell lung cancer (SCLC)

AND ALL of the following:



**BlueCross
BlueShield**

Federal Employee Program.

**ZEPZELCA
(lurbinectedin)**

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for myelosuppression and hepatotoxicity
- c. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zepzelca and for 6 months after the final dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zepzelca and for 4 months after the final dose

Prior - Approval *Renewal* Limits

Same as above